Diadem Srl

Diadem Srl develops innovative blood-based diagnostics aimed at the early detection of Alzheimer's disease, utilizing advanced technology to enhance patient care and clinical research. Founded in 2012 in Brescia, Italy, Diadem specializes in blood diagnostics for Alzheimer's disease. The company's recent strategic move includes a Series B funding round, raising EUR 10 million on March 28, 2022, from CDP Venture Capital and Panakes Partners. Paul Kinnon serves as CEO.

Diadem focuses on the development of blood-based diagnostics, particularly its flagship product, AlzoSure™, which detects specific conformations of the p53 protein associated with Alzheimer's disease. AlzoSure™ is designed for early, non-invasive diagnosis, primarily used by healthcare providers, research institutions, and pharmaceutical companies involved in Alzheimer’s treatment and clinical trials. In 2023, Diadem reported a revenue of EUR 0, with an EBITDA of EUR -952,866. 7, indicating the company's current financial position as it continues to develop its diagnostic products.

Following its Series B funding in March 2022, which raised EUR 10 million, Diadem plans to enhance the global development and commercialization of its first blood test, AlzoSure™. The funding will support the introduction of new products and facilitate entry into new markets, particularly targeting regions with significant Alzheimer's initiatives, including North America and Europe.